Annovis Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-2.7%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$1.69next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Expected Completion of PD OLE Study Enrollment | 31 Dec 2026 |
| Anticipated NDA Submission for Buntanetap (Symptomatic AD) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Phase 3 Alzheimer's Disease Trial Enrollment Progress Quarterly85.0Target: 100% (Full Enrollment)
Parkinson's Disease Open-Label Extension (OLE) Study Enrollment Progress Quarterly40.0Target: 100% (Full Enrollment)
Cash and Cash Equivalents Quarterly14.2MTarget: Sufficient capital to fund operations through clinical readouts
Watch Items
- Phase 3 AD Trial Full Enrollment MilestoneTrigger: Summer 2026Action: Confirm completion of enrollment to lock in the timeline for the 6-month symptomatic readout.
- Parkinson's Disease OLE Study Full Enrollment MilestoneTrigger: Q4 2026Action: Verify enrollment completion to ensure long-term safety and tolerability data collection remains on track.
- Cash Runway and Capital Raising ActivitiesTrigger: Cash reserves falling below $10 million without additional non-dilutive or dilutive fundingAction: Evaluate capital-raising options (such as public offerings or strategic partnerships) to extend the runway beyond Q3 2026.
- Regulatory NDA Pathway Engagement with FDATrigger: Early 2027Action: Initiate formal FDA discussions regarding the symptomatic treatment NDA submission for buntanetap in Alzheimer's disease.
Research as of 19 Jun 2026